Get the Stockscreener App
0.00
100.00%
-0.0973
After Hours:
.10
0.10
+
Zomedica Corp stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Zomedica Pharmaceuticals Corp., a development stage veterinary diagnostic and pharmaceutical company, engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company's lead drug product candidate is ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in dogs. It is also developing ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in cats; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. The company has a collaboration agreement with Celsee Diagnostics, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. Zomedica Pharmaceuticals Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
See More
Previous Close:
$0.0973
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$120.44M
Revenue:
$25.19M
Net Income/Loss:
$-34.53M
P/E Ratio:
0.00
EPS:
-0.036
Net Cash Flow:
$-20.62M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.1677
Zomedica Corp Stock (ZOM) Company Profile
Name
Zomedica Corp
Sector
Phone
734-369-2555
Address
100 Phoenix Drive, Suite 190, Ann Arbor, MI
Compare ZOM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZOM
Zomedica Corp
|
0.00 | 120.44M | 25.19M | -34.53M | -20.62M | -0.036 |
|
RGC
Regencell Bioscience Holdings Ltd
|
22.99 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.18 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.25 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.34 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.01 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Zomedica Corp Stock (ZOM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-23 | Initiated | Dawson James | Buy |
Zomedica Corp Stock (ZOM) Latest News
Zomedica Pharmaceuticals Corp. (ZOM.V) (CVE:ZOM) Shares Down 6.6% – Time to Sell? - Defense World
WTR Biotech Spotlight Podcast Recap Zomedica Corp. (ZOMDF) - Smartkarma
Transcript : Zomedica Corp.Special Call - marketscreener.com
Revolutionary Breakthrough: Zomedica's New Equine Insulin Test Eliminates Manual Dilution, Sets Industry Record - Stock Titan
Director’s Bold Move: Massive Stock Purchase in Zomedica! - TipRanks
Zomedica Unveils Exclusive Fourth Friday at Four Webinar Series to Explore Cutting-Edge Veterinary Innovations - ACCESS Newswire
Zomedica Unveils Game-Changing Veterinary Tech Portfolio in New Monthly Expert Webinar Series - Stock Titan
Zomedica Corp. (ZOMDF) Reports Q1 Loss, Lags Revenue Estimates - MSN
Transcript : Zomedica Corp., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
Zomedica Reports Q1 2025 Growth Amid Strategic Expansion - TipRanks
Zomedica Announces First Quarter 2025 Financial Results: Revenue of $6.5 Million; 68% Gross Margin, and $65 Million in Liquidity to Support Growth - ACCESS Newswire
Leading Proxy Advisory Firm ISS Recommends Zomedica Shareholders Vote "FOR" Proposed Reverse Stock Split - ACCESS Newswire
Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease - ACCESS Newswire
Zomedica Corp (ZOMDF) Q1 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Zomedica Corp (ZOMDF) Q1 2025 Earnings Report Preview: What To E - GuruFocus
Zomedica Launches Groundbreaking Equine Asthma Clinical Registry Featuring PulseVet(R) Shock Wave Therapy - ACCESS Newswire
Company’s flying speeder bike is like something from ‘Star Wars’ - The Herald Palladium
Zoo uses ‘Blind Date’ technique to get rare animals to mate - The Herald Palladium
Zomedica to Report First Quarter 2025 Financial Results with a Business Update on Thursday, May 15, 2025 at 4:30 pm ET - ACCESS Newswire
The United States Eventing Association Names Zomedica’s PulseVet(R) as the Official Shock Wave of the USEA - ACCESS Newswire
Zomedica CFO resigns, interim replacement named By Investing.com - Investing.com Nigeria
Zomedica CFO resigns, interim replacement named - Investing.com
Zomedica CFO Scott Jordan Resigns, Interim Replacement Named - TipRanks
US Equestrian Names Zomedica’s PulseVet System as the Official Shock Wave Therapy of US Equestrian Team Veterinarians - ACCESS Newswire
Zomedica Announces Designation of PulseVet® System as the Official Shock Wave Therapy of the National Cutting Horse Association - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
Zomedica Appoints Dr. Pamela Nichols, DVM to Board of Directors - ACCESS Newswire
Zomedica Corp. Announces Transition to OTCQB Venture Market - ACCESS Newswire
Zomedica Introduces Enhanced Audio Features for the VETGuardian(R) Zero-touch Vital Signs Remote Monitoring System - ACCESS Newswire
Should You Sell IDEXX Laboratories (IDXX)? - Yahoo Finance
Zomedica Announces Third Quarter 2024 Financial Results: Revenue Up 10% to $7 Million; 72% Gross Margin, and $78 Million in Liquidity to Support Growth - ACCESS Newswire
Zomedica Corp. (ZOMDF): Among Stocks Insiders Were Buying In Q1 2025 - Insider Monkey
20 Stocks Insiders Were Buying In Q1 2025 - Insider Monkey
Is Zomedica Corp. (ZOMDF) the Cheapest Stock Insiders Are Buying In March? - Insider Monkey
15 Cheapest Stocks Insiders Are Buying In March - Insider Monkey
Zscaler, Rocket Lab, American Tower, Intuit, and Zomedica: Insider Moves Unveiled! - TipRanks
Zomedica director Rodney Williams acquires $6,900 in stock By Investing.com - Investing.com Canada
Zomedica director Rodney Williams acquires $6,900 in stock - Investing.com
Zomedica’s CFO Jordan Scott acquires $18,600 in common stock By Investing.com - Investing.com Canada
Zomedica director Christopher MacLeod buys $8,437 in stock - Investing.com India
Zomedica’s CFO Jordan Scott acquires $18,600 in common stock - Investing.com
Zomedica Corp Stock (ZOM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.54%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):